SLC7A11 and myeloid sarcoma: Recent studies demonstrated that the xCT subunit of system xc- (responsible for the activity of this antiporter) is upregulated in postmortem CNS tissues from both MS patients and MS rodent models [6] and that it might be a promising PET imaging biomarker of disease progression in EAE rats [8].